Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1

AbbVie

Status: Completed

Conditions: Chronic Hepatitis C Virus

Study type: Observational

Funder types: Industry

Identifiers

NCT02629172

P15-336

Details and patient eligibility

About

The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.

Enrollment: 3,043 patients

Sex: All

Ages: Under 120 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HCV genotype 1 patients treated with paritaprevir/ritonavir/ombitasvir in daily practice

Exclusion criteria

• Patients who have been previously treated with paritaprevir/ritonavir/ombitasvir

Trial design

3,043 participants in 1 patient group

Chronic infection of hepatitis C virus (HCV) Genotype 1 (GT1)

Description:

Participants with confirmed chronic hepatitis C genotype 1, receiving paritaprevir/ritonavir/ombitasvir according to standard of care and in line with the current local label